Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706939 · ClinicalTrials.gov registry record · Phase 3
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
A Phase 3 study of Squamous Cell Carcinomas, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01706939: Active Phase 3 study of Squamous Cell Carcinomas, sponsored by Icahn School of Medicine at Mount Sinai.
NCT01706939 is a Phase 3 study of Squamous Cell Carcinomas that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 23 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01706939, a Phase 3 study of Squamous Cell Carcinomas, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.
Primary Outcome
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation.
Conditions Studied
Interventions
- DRUG Carboplatin
- RADIATION Standard Dose Radiation
- RADIATION Reduced Dose Radiation
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-09-01 |
| Est. Completion | 2035-05-01 |
| Phase | Phase 3 |
What the registry record for NCT01706939 still lists
NCT01706939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Squamous Cell Carcinomas appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT01706939 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01706939 about?
NCT01706939 is a clinical study titled "The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer". This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups. The study hypothesis is that LRC and PFS at 3 years for reduced dose CRT are non-inferior to standard dose CRT.
What is the current status of trial NCT01706939?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2012-09-01. Estimated completion is 2035-05-01.
What conditions does trial NCT01706939 study?
This clinical trial studies the following conditions: Squamous Cell Carcinomas.
What interventions are being tested in trial NCT01706939?
The interventions under investigation include: Carboplatin (DRUG), Standard Dose Radiation (RADIATION), Reduced Dose Radiation (RADIATION).
Who is sponsoring clinical trial NCT01706939?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01706939 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01706939's enrollment target sits among peer trials
23 1952nd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI